阿諾醫藥 ANL 深 滬
已收盤 02-06 16:00:00 美东时间
10.01
-0.130
-1.28%
華盛通- 最 高10.14
- 今 開10.14
- 成交量 41.44万股
- 最 低 9.12
- 昨 收 10.14
- 總市值 3.69亿
- 52周最高 12.0899
- 市盈率 靜 --
- 換手率 1.12%
- 52周最低 0.8786
- 委 比 -89.49%
- 總股本 3690.03万
- 歷史最高 19.2999
- 量 比 0.14
- 振 幅 10.06%
- 歷史最低 0.8786
- 每 手 1
- 風險率 1.22%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Adlai Nortye Announces $140M Private Placement Equity Financing
Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has entered into securities
02-03 20:45
美股牛股 | 德克斯户外涨近20%，财报表现优异；磷化铟公司AXTI涨超13%
TechCreate Group Ltd. Class A涨100.1%；阿诺医药涨62.8%；罗致恒富涨27.8%
01-31 10:13
美股牛股 | 矽晶电信飙升近30%，Q4营收同比大增17%；西南航空大涨18%
矽晶电信飙升近30%，Q4营收同比大增17%；摩丁制造大涨20%，分拆技术业务并与Gentherm合并，以优化公司结构；西南航空大涨18%，Q4每股收益及全年指引均超预期>>
01-30 18:27
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Adlai Nortye (NASDAQ:ANL) stock moved upwards by 44.5% to $2.37 during...
2025-12-29 20:05
Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China
Adlai Nortye与ASK Pharm签署AN9025独家许可协议，授权其在 mainland China, Hong Kong, and Macau 开发、生产和商业化。Adlai Nortye将保留全球权利，预计获得高达16亿元人民币的总付款，包括首付款、里程碑付款及销售分成。AN9025是潜在同类最佳的pan-RAS(ON)抑制剂，针对多种肿瘤类型的RAS突变，预计2026年Q1启动I期临床试验。此次合作旨在加速RAS突变癌症患者的治疗开发。
2025-12-29 11:00
Adlai Nortye Ltd. Shareholders Approve Redomiciliation to Singapore
Adlai Nortye Ltd. Sponsored ADR ( ($ANL) ) has provided an announcement. Adlai ...
2025-12-03 19:27
Adlai Nortye to Participate in Upcoming Investor Conferences
Adlai Nortye Ltd. announced that its management team will participate in two upcoming investor conferences: the 8th Annual Evercore Healthcare Conference on December 2, 2025, in Coral Gables, Florida, and the 36th Oppenheimer Annual Healthcare Life Sciences Conference on February 25-26, 2026. The company, focused on innovative cancer therapies, is developing therapies in two key areas: next-generation cancer immunotherapies and RAS-targeting ther...
2025-11-21 13:00
Adlai Nortye Ltd. Plans Redomiciliation to Singapore
Adlai Nortye Ltd. Sponsored ADR ( ($ANL) ) just unveiled an announcement. Adlai...
2025-10-23 05:28
Adlai Nortye to Present Short Talk on AN4035 Preclinical Results at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Adlai Nortye Ltd. will present AN4035, a novel CEACAM5-targeting antibody drug conjugate (ADC) with a proprietary pan-RAS(ON) inhibitor payload, at the AACR-NCI-EORTC conference. AN4035 demonstrates strong intracellular retention, potent cytotoxicity in CEACAM5-positive/RAS-addicted cancers, and a favorable toxicology profile. The Company highlights its potential to overcome limitations of existing pan-RAS(ON) inhibitors by targeting tumors speci...
2025-10-22 04:00
